CA2603359A1 - Human glp-1 mimetibodies, compositions, methods and uses - Google Patents

Human glp-1 mimetibodies, compositions, methods and uses Download PDF

Info

Publication number
CA2603359A1
CA2603359A1 CA002603359A CA2603359A CA2603359A1 CA 2603359 A1 CA2603359 A1 CA 2603359A1 CA 002603359 A CA002603359 A CA 002603359A CA 2603359 A CA2603359 A CA 2603359A CA 2603359 A1 CA2603359 A1 CA 2603359A1
Authority
CA
Canada
Prior art keywords
glp
seq
mimetibody
drug
polypeptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002603359A
Other languages
English (en)
French (fr)
Inventor
Karyn T. O'neil
Kristen Picha
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Biotech Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2603359A1 publication Critical patent/CA2603359A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/48Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575Hormones
    • C07K14/605Glucagons
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2318/00Antibody mimetics or scaffolds
    • C07K2318/10Immunoglobulin or domain(s) thereof as scaffolds for inserted non-Ig peptide sequences, e.g. for vaccination purposes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Immunology (AREA)
  • Obesity (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CA002603359A 2005-03-28 2005-12-22 Human glp-1 mimetibodies, compositions, methods and uses Abandoned CA2603359A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US2005097175 2005-03-28
USPCT/US2005/097175 2005-03-28
PCT/US2005/046884 WO2007081302A2 (en) 2005-03-28 2005-12-22 Human glp-1 mimetibodies, compositions, methods and uses

Publications (1)

Publication Number Publication Date
CA2603359A1 true CA2603359A1 (en) 2007-07-19

Family

ID=38256744

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002603359A Abandoned CA2603359A1 (en) 2005-03-28 2005-12-22 Human glp-1 mimetibodies, compositions, methods and uses

Country Status (12)

Country Link
EP (1) EP1871811A4 (enExample)
JP (1) JP2008546373A (enExample)
KR (1) KR20080005378A (enExample)
CN (1) CN101389346A (enExample)
AU (1) AU2005339797A1 (enExample)
BR (1) BRPI0520168A2 (enExample)
CA (1) CA2603359A1 (enExample)
CR (1) CR9481A (enExample)
IL (1) IL186307A0 (enExample)
MX (1) MX2007011975A (enExample)
NO (1) NO20075272L (enExample)
WO (1) WO2007081302A2 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200843794A (en) * 2006-12-21 2008-11-16 Centocor Inc Use of long-acting GLP-1 receptor agonists to improve insulin sensitivity and lipid profiles
CN111574583B (zh) * 2020-04-10 2021-06-25 上海海路生物技术有限公司 蛋白复性试剂及其应用
CN120741086A (zh) * 2024-07-26 2025-10-03 荣耀终端股份有限公司 模拟人体组织液及其制备方法和应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000046380A2 (en) * 1999-02-08 2000-08-10 Chiron Corporation Fibroblast growth factor receptor-immunoglobulin fusion
NZ525577A (en) * 2000-12-07 2005-05-27 Lilly Co Eli Glucagon-Like Peptide 1 heterologous fusion proteins for the treatment of non-insulin dependent diabetes mellitus
JP2006504406A (ja) * 2002-06-28 2006-02-09 セントカー・インコーポレーテツド 哺乳動物のch1欠失ミメティボディ、組成物、方法および使用
AU2003256336A1 (en) * 2002-06-28 2004-01-19 Centocor, Inc. Mammalian epo mimetic ch1 deleted mimetibodies, compositions, methods and uses
EP1644416A4 (en) * 2003-06-30 2007-08-29 Centocor Inc ANTI-TARGET AND GENETICALLY MODIFIED IMMUNOGLOBULIN-DERIVED PROTEINS, COMPOSITIONS, METHODS AND USES
AU2005231359A1 (en) * 2004-03-31 2005-10-20 Centocor, Inc. Human GLP-1 mimetibodies, compositions, methods and uses

Also Published As

Publication number Publication date
WO2007081302A3 (en) 2008-11-13
CN101389346A (zh) 2009-03-18
EP1871811A4 (en) 2009-07-22
EP1871811A2 (en) 2008-01-02
BRPI0520168A2 (pt) 2009-04-22
AU2005339797A1 (en) 2007-07-19
NO20075272L (no) 2007-12-28
KR20080005378A (ko) 2008-01-11
CR9481A (es) 2009-01-14
MX2007011975A (es) 2008-03-14
WO2007081302A2 (en) 2007-07-19
JP2008546373A (ja) 2008-12-25
IL186307A0 (en) 2008-01-20

Similar Documents

Publication Publication Date Title
US8071103B2 (en) Pharmaceutical composition comprising a human GLP-1 mimetibody
US20070128193A1 (en) GLP-1 agonists, compositions, methods and uses
US20070135338A1 (en) Human GLP-1 mimetibodies, compositions, methods and uses
US7241733B2 (en) Mammalian EPO mimetic CH1 deleted mimetibodies, compositions, methods and uses
AU2004277884B2 (en) Human EPO mimetic hinge core mimetibodies, compositions, methods and uses
WO2004002417A2 (en) Mammalian ch1 deleted mimetibodies, compositions, methods and uses
CA2673657A1 (en) Use of long-acting glp-1 receptor agonists to improve insulin sensitivity and lipid profiles
CA2603359A1 (en) Human glp-1 mimetibodies, compositions, methods and uses
CN101426519A (zh) 人glp-1模拟体、组合物、方法和用途

Legal Events

Date Code Title Description
FZDE Discontinued